Corbus制药控股 CRBP 深 沪
已收盘 05-08 16:00:00 美东时间
10.96
+0.090
+0.83%
华盛通- 最 高11.28
- 今 开10.88
- 成交量 24.10万股
- 最 低 10.79
- 昨 收 10.87
- 总市值 1.94亿
- 52周最高 20.56
- 市盈率 静 --
- 换手率 1.36%
- 52周最低 6.72
- 委 比 -35.69%
- 总股本 1773.65万
- 历史最高 323.40
- 量 比 0.61
- 振 幅 4.51%
- 历史最低 3.00
- 每 手 1
- 风险率 2.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45
Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.
04-30 00:16
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings April 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola Co, Mondelez and Zeta Global Holdings Corp on Wednesday. HIGHLIGHTS * Coca-Cola Co KO.
04-29 16:01
Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections
Corbus Pharmaceuticals ( ($CRBP) ) has provided an announcement. On April 15, 2...
04-17 05:12
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone
Corbus Pharmaceuticals ( ($CRBP) ) has shared an announcement. On April 14, 202...
04-14 21:06
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.
04-07 23:56
Corbus Pharmaceuticals Announces Broad Alignment With FDA On Registration Path For CRB-701
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancerUpdated CRB-701 monotherapy data accepted
04-07 20:10
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Corbus Pharmaceuticals' CEO, Yuval Cohen, will participate in the BMO 2026 Metabolic Health Summit on March 24. Corbus is developing CRB-913, an oral CB1 inverse agonist for obesity, showing promising results in Phase 1 studies. The company expects to complete Phase 1b trials in summer 2026. The summit will discuss metabolic disease treatments, with networking opportunities. Corbus focuses on innovative therapies for obesity and oncology.
03-18 12:00
美股机会日报 | 伊朗国家媒体：英伟达、谷歌等美国巨头或成打击目标！美国2月通胀数据将于20:30公布
伊朗国家媒体：英伟达、谷歌等美国巨头或成打击目标！美国2月通胀数据将于20:30公布，市场预计趋于平稳；甲骨文盘前涨超9%，上季业绩大超预期>>
03-11 20:16
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
